Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 813 results for "daiichi sankyo"

Daiichi Sankyo launches methemoglobinemia drug in Japan

Daiichi Sankyo Company, Limited, a Japanese pharmaceutical company, has launched Methylene Blue injection 50mg, indicated for the treatment of methemoglobinemia. Methylene Blue is one of the agents publicly offered for development by the Review ... Individual.com, 4 days ago
[x]  
Bio Spectrum Asia

Daiichi Sankyo Tightens Belt and Kicks Off Cuts to Total 16%

March 24, 2015 By Mark Terry , BioSpace.com Breaking News Staff Tokyo-based Daiichi Sankyo, Inc. , which has U.S. headquarters in Parsippany, N.J., announced today it will begin laying off 16 percent of its U.S. staff starting Monday March ...
 BioSpace6 days ago AstraZeneca to commercialize Daiichi Sankyo's OIC drug...  Bio Spectrum Asia1 week ago AstraZeneca and Daiichi Sankyo to Jointly Commercialize Movantik in the U.S.  Pharmaceutical & Medical Packaging News6 days ago ViewPoints: AstraZeneca steps up externalisation strategy with Daiichi-Sankyo/Movantik deal  FirstWord Pharma1 week ago
[x]  
European Pharmaceutical Review

Daiichi Sankyo eyes valuation gain in Ranbaxy deal

TOKYO -- Japan's Daiichi Sankyo expects a valuation gain of about 340 billion yen ($2.81 million) from offloading subsidiary Ranbaxy Laboratories to India's Sun Pharmaceutical Industries, according to a Wednesday announcement. The gain comes from ...
 Nikkei Asian Review4 days ago Announcement Regarding Closure of Merger Between Daiichi Sankyo Subsidiary Ranbaxy and Sun Pharma  Noodls5 days ago Daiichi Sankyo's Subsidiary Ranbaxy merged with Sun...  Bio Spectrum Asia4 days ago Sun Pharma completes Ranbaxy merger  India Today5 days ago
[x]  
Reuters

DAIICHI SANKYO : N.C. to get share of $39 million in doctor kickback case

March 25 -- RALEIGH -- Drug maker Daiichi Sankyo will pay more than $39 million in a settlement regarding alleged kickbacks to get doctors to prescribe the company's drugs, according to a news release from N.C. Attorney General Roy Cooper . The ...
 4 Traders4 days ago Doctor outreach at heart of Daiichi Sankyo's $39M settlement with DoJ  FiercePharma1 week ago Daiichi Sankyo to pay $39 million to settle U.S. kickback claims: DOJ  Reuters2 months ago

AstraZeneca plc (ADR) And Daiicho Sankyo To Co-Market OIC Drug Movantik In The US

AstraZeneca plc (ADR) ( NYSE:AZN ) announced on Thursday an agreement with Daiichi Sankyo Co LT ( OTCMKTS:DSKYF ) to jointly market its constipation drug MOVANTIK in the US. MOVANTIK is a first-in-class mu receptor-targeting drug designed to ...
 Mr Top Step1 week ago AstraZeneca, Daiichi Sankyo to Sell Constipation Drug in U.S.  iMarketReports1 week ago AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog  Yahoo! Finance1 week ago

UPDATED: Daiichi Sankyo starts layoff drive with 16% cuts at HQ

Daiichi Sankyo's Parsippany, NJ, facility Times have been tough for Daiichi Sankyo, and they're about to get tougher for some of the Japanese company's U.S. staffers. The drugmaker is cutting its commercial headquarters staff by 16% on Monday, ...
 FiercePharma5 days ago Daiichi Sankyo starts layoff drive with 16% cuts at HQ  FierceMedicalDevices5 days ago

Georgia Enters National Settlement with Pharmaceutical Company Daiichi Sankyo to Resolve Kickback Allegations

 Noodls1 week ago Press Release: A.G. SCHNEIDERMAN ANNOUNCES KICKBACK SETTLEMENT WITH PHARMA MANUFACTURER DAIICHI-SANKYO  iMarketReports1 week ago A.G. Schneiderman Announces Kickback Settlement With Pharma Manufacturer Daiichi-Sankyo  Noodls1 week ago

Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights

AstraZeneca ( $AZN ) announced a partnership with Daiichi Sankyo to sell its opioid-induced constipation therapy Movantik in the U.S. for a $200 million upfront fee from the Japanese drugmaker followed by sales-related payments of up to $625 ...
 Fierce BioMarkers1 week ago Daiichi shells out $200M-plus to help AstraZeneca launch Movantik  FiercePharma1 week ago ASTRAZENECA : Teams With Daiichi Sankyo To Sell Movantik In US  4 Traders1 week ago AstraZeneca Teams With Daiichi Sankyo To Sell Movantik In US  London South East1 week ago
New York Business Journal

DAIICHI SANKYO : State to Receive $690,000 Under Settlement with New-Jersey-Based Drug Maker over Alleged Unlawful Incentives to Physicians

Acting Attorney General John J. Hoffman announced today that New Jersey will receive a total of $690,000 as a result of its participation in a global settlement with pharmaceutical manufacturer Daiichi Sankyo, Inc. , that resolves allegations the ...
 4 Traders1 week ago New York to get $2.4M in settlement with Daiichi Sankyo  New York Business Journal1 week ago
Invezz

GSK share price: Company receives approval for three products in Japan

GlaxoSmithKline Plc (LON:GSK) has gained approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Encruse Ellipta product to be used to treat patients with chronic obstructive pulmonary disease (COPD). The umeclidinium drug ...
 Invezz4 days ago GSK receives approval for Encruse® Ellipta® in Japan for the treatment of COPD  Noodls4 days ago GSK receives approval for Encruse Ellipta in Japan for the treatment of COPD  FirstWord Pharma4 days ago GLAXOSMITHKLINE : GSK receives approval for Encruse® Ellipta® in Japan for the treatment of COPD  4 Traders4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - daiichi sankyo
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less